Serrapeptase for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Serrapeptase for Health & Longevity

Created on 08/14/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

Serrapeptase is a protein-digesting enzyme first used for short swelling and mucus courses, later sold as a daily supplement. Small dental, sinus, and breast-fullness trials show mixed benefit; larger unpublished trials found no ankle or sputum advantage. Absorption is unproven. Longevity and plaque claims are untested. Short-trial side effects are similar to placebo; rare lung inflammation and theoretical bleeding interaction. (Full Review)

Protocol

Historical drug schedule
10 mg three times daily after meals
1–2 weeks for swelling; same 30 mg/day for 2–4 weeks for mucus
Supplement practice
10–60 mg/day
About 20,000–120,000 serrapeptase units on an empty stomach; often split every 8 hours; Health Canada cap 60 mg/day
Time of day
Split morning, afternoon, and evening
Matches the short detection window; night-only dosing is a consumer pattern, not a trial standard
Time to effect
Swelling and pain
Days 1–7
Window measured in swelling and pain trials
Mucus-property changes
2–4 weeks
Assessment time in airway mucus-property trials
Plaque or amyloid claims
No human time course
No controlled vascular or cognitive trial

Benefits

Contraindications
  • Known hypersensitivity to serrapeptase or Serratia enzymes
  • Active or recent significant bleeding, or planned surgery within about 2 weeks
  • Current anticoagulant or dual-antiplatelet therapy unless bleeding risk is already being managed
  • Pregnancy or lactation (no adequate safety data)
  • Prior drug-induced eosinophilic pneumonia or unexplained eosinophilia
  • Active untreated abscess or deep infection
  • Children
    •
Key Interactions
  • NSAIDs (ibuprofen, diclofenac, aceclofenac)
  • Other proteolytic supplements (nattokinase, lumbrokinase, bromelain, high-dose systemic protease blends)
  • Antibiotics (cefotiam, sulbenicillin, ofloxacin)
  • Food protein at the same time
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Gastrointestinal discomfort; Hypersensitivity and ordinary skin reactions; Drug-induced eosinophilic pneumonia
    •
  • Speculative: Increased bleeding; Severe blistering skin reactions; Spread of a walled-off infection
    •

Monitoring

Marker Target Why
hs-CRP <0.7 mg/L Tracks whether systemic inflammation is present to modify
Eosinophils <3% or <300 cells/µL Screens for evolving drug-lung or allergic signal
Fibrinogen 200–300 mg/dL Baseline clot protein if fibrinolytic use is the rationale
PT/INR 0.9–1.1 if not anticoagulated Detects a bleeding-risk shift on combined agents
Hemoglobin No enzyme-specific target; track change from own baseline Flags occult blood loss

Cadence: Baseline before start; if used, about 2–4 weeks, then every 3–6 months during continued use; promptly if cough, rash, or bruising appears

Qualitative Assessment

  • Sinus pressure, nasal discharge, and sputum stickiness
  • Surgical-site swelling, bruise size, and mouth opening
  • New cough, breathlessness, fever, or rash
  • Unusual bruising, nosebleeds, or dark stool
  • Energy and local pain scores versus the person's own week-zero notes
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.